latest news releases from the newsroom
Extended Follow-up of Renal Cancer Patients Provides New Support for Antisoma's AS1411
LONDON and PHILADELPHIA, Nov. 16, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) announces the presentation of long-term follow-up data from the phase I trial of its aptamer drug AS1411. The new data extend results presented at the ASCO meeting in May, where promising signs of anti-cancer activity were reported in the trial's three renal cancer patients. At that time, one of these patients had shown a near-complete response, having experienced dramatic shrinkage of a large tumour. This patient is still in remission 16 months after treatment. The other two renal cancer patients had shown prolonged stable disease, one for 9 months and one ongoing at the time of ASCO. The latter patient is now known to have remained stable for 15 months before relapse. This update will be presented today at the AACR-NCI-EORTC meeting in Philadelphia by Professor Donald Miller, a co-inventor of AS1411 and Director of the Brown Cancer Center at the University of Louisville, where the trial was conducted.
Management changes in TeliaSonera International Carrier
STOCKHOLM, Sweden, Nov. 16, 2005 (PRIMEZONE) -- Mr. Ingvar Larsson has been appointed new President of TeliaSonera International Carrier, a pure wholesale provider of network services for fixed and mobile operators, carriers and service providers. The carrier operation offers international IP and voice services as well as high capacity bandwidth to destinations in Europe and across the Atlantic based on wholly owned infrastructure. Ingvar Larsson will assume his new responsibilities from January 1, 2006.
CDMA Development Group
CDMA2000 EV-DO Revision B Standard to be Published in First Quarter of 2006
HONG KONG, Nov. 16, 2005 (PRIMEZONE) -- The CDMA Development Group (CDG) (www.cdg.org) today announced that the standard for CDMA2000 EV-DO Revision B is on schedule to be published in the first quarter of 2006. Revision B is a further enhancement to the CDMA2000 standard and significantly increases the data throughput up to 73.5 Mbps in the forward link and 27 Mbps in the reverse link by dynamically allocating multiple radio frequency (RF) carriers across wider frequency blocks.
Glancy Binkow & Goldberg LLP
Glancy Binkow & Goldberg LLP, Representing Investors Who Purchased Barrier Therapeutics, Inc., Announces Class Action Lawsuit and Seeks to Recover Losses
LOS ANGELES, Nov. 15, 2005 (PRIMEZONE) -- Notice is hereby given by Glancy Binkow & Goldberg LLP that a Class Action lawsuit was filed in the United States District Court for the District of New Jersey on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired securities of Barrier Therapeutics, Inc. ("Barrier" or the "Company")(Nasdaq:BTRX), between April 29, 2004 and June 29, 2005 (the "Class Period"), including those who purchased the common stock of Barrier pursuant and/or traceable to the Company's Initial Public Offering on April 29, 2004 and/or its Secondary Offering on February 9, 2005.
Aeroflex WLAN and GSM/EDGE Measurement Suites Speed PXI-Based Testing for RFICs and Mobile Handsets
HONG KONG, Nov. 16, 2005 (PRIMEZONE) -- 3G World Congress & Exhibition 2005 -- Booth No. 1341 -- As today's cellular phones and PDAs become capable of connection into wireless local area networks (WLAN), Aeroflex (Nasdaq:ARXX) is keeping pace by releasing a new measurement suite for WLAN as well as expanding features of the existing GSM/EDGE measurement suite. These measurement suites for use with Aeroflex's PXI modular RF platform will help speed up testing during the development and manufacture of WLAN and cellular devices using a single Aeroflex test system. Aeroflex's modular RF platform achieves greater flexibility and speed than equivalent conventional rack-based test systems by leveraging the inherent benefits of PXI, an industry open standard for lower cost, higher speed instrumentation. PXI-based test systems for mobile handset manufacturing combined with easy-to-implement and speed-optimized measurement suites have accelerated test times by as much as five times.